Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2004;104:433-442
© 2004 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cykert, S.
Right arrow Articles by Hansen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cykert, S.
Right arrow Articles by Hansen, C.

ORIGINAL RESEARCH

Tamoxifen for Breast Cancer Prevention: A Framework for Clinical Decisions

Samuel Cykert, MD*{dagger}, Nancy Phifer, MD{dagger} and Charles Hansen, MA{dagger}

From the *Cecil G. Sheps Center for Health Services Research, the University of North Carolina, Chapel Hill; and {dagger}The Internal Medicine Program and the Greensboro Area Health Education Center of the Moses Cone Health System, Greensboro, North Carolina.

Address reprint requests to: Samuel Cykert, MD, Associate Professor of Medicine (UNC-CH), Chief, Internal Medicine Program, Moses Cone Hospital, 1200 North Elm Street, Greensboro, NC 27401; e-mail: sam.cykert{at}mosescone.com.

OBJECTIVE: Given the potential side effects and an uncertain survival benefit, decisions about tamoxifen treatment for the primary prevention of breast cancer remain complex. Primary care providers, including gynecologists, will need to counsel patients regarding this form of preventive care. In this report, we update cost-effectiveness calculations for tamoxifen chemoprevention and establish reasonable parameters for clinicians’ use.

METHODS: We performed a cost-effectiveness analysis that compared women aged 50 years who were treated with tamoxifen for 5 years with an untreated cohort. In the base model, we assumed a 3.4% 5-year breast cancer risk. Quality-of-life estimates for important outcomes (breast cancer, endometrial cancer, deep venous thrombosis, pulmonary embolism, stroke, metastatic cancer, and hot flushes) were obtained from 106 women. Probabilities and costs of outcomes were derived from the Breast Cancer Chemoprevention Trial and other published estimates. Broad sensitivity analyses were performed. Cost per quality-adjusted life-year gained as a result of tamoxifen breast cancer prevention was the main outcome measure.

RESULTS: The use of tamoxifen led to a remaining life expectancy of 26.07 quality-adjusted life-years compared with 25.97 without treatment. The cost per quality-adjusted life-year gained was $43,300. Sensitivity analysis revealed that younger age, the absence of the uterus, higher initial risk of breast cancer, increased fear of curable breast cancer, and reduced tamoxifen cost further favored treatment.

CONCLUSION: Tamoxifen chemoprevention is cost-effective for women aged 40–50 years who are at significant breast cancer risk. Whether this holds true for older women depends on the initial breast cancer risk, fear of breast cancer, and presence of the uterus.

LEVEL OF EVIDENCE: III




This article has been cited by other articles:


Home page
 The OncologistHome page
E. A. Perez
Appraising Adjuvant Aromatase Inhibitor Therapy
Oncologist, November 1, 2006; 11(10): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
D. J. Rouse
Primary Prevention of Breast Cancer: Whither Tamoxifen?
Obstet. Gynecol., September 1, 2004; 104(3): 431 - 432.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Obstetricians and Gynecologists.